324 reports of this reaction
2.4% of all BINIMETINIB reports
#11 most reported adverse reaction
SEROUS RETINAL DETACHMENT is the #11 most commonly reported adverse reaction for BINIMETINIB, manufactured by Array BioPharma Inc.. There are 324 FDA adverse event reports linking BINIMETINIB to SEROUS RETINAL DETACHMENT. This represents approximately 2.4% of all 13,446 adverse event reports for this drug.
Patients taking BINIMETINIB who experience serous retinal detachment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEROUS RETINAL DETACHMENT is a less commonly reported adverse event for BINIMETINIB, but still significant enough to appear in the safety profile.
In addition to serous retinal detachment, the following adverse reactions have been reported for BINIMETINIB:
The following drugs have also been linked to serous retinal detachment in FDA adverse event reports:
SEROUS RETINAL DETACHMENT has been reported as an adverse event in 324 FDA reports for BINIMETINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEROUS RETINAL DETACHMENT accounts for approximately 2.4% of all adverse event reports for BINIMETINIB, making it a notable side effect.
If you experience serous retinal detachment while taking BINIMETINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.